Blog
Ozempic vs Wegovy vs Mounjaro —
Which Weight Loss Injection Actually Works?
A complete, no-nonsense breakdown of the three most talked-about weight loss injections of 2025 — with real clinical data, side effects, and exact costs in the USA & UK.
1 The Weight Loss Drug Revolution
Something remarkable has happened in medicine over the last few years. For decades, truly effective weight loss medications were considered somewhat of a holy grail — promising in theory, but always falling short in practice. Then came a new class of drugs called GLP-1 receptor agonists, and everything changed.
Three names dominate the conversation today: Ozempic, Wegovy, and Mounjaro. You've seen them in the news. Your favorite celebrities are rumored to be using them. Your doctor may have even brought them up. But with so much hype and misinformation circulating, it can be hard to get straight answers.
That's exactly what this guide is for. Drawing on clinical trial data, pricing from real UK and US pharmacies, and over 10 years of pharmaceutical knowledge, I'm going to give you the most honest, complete comparison you'll find — so you can have an informed conversation with your healthcare provider.
Let's start with the basics: all three medications work by mimicking natural hormones your body releases after you eat, signaling fullness to the brain and slowing digestion. But their differences — in active ingredients, dosage, FDA approval status, and effectiveness — matter a great deal.
2 What is Ozempic?
Ozempic is perhaps the most recognized name in this group, partly due to viral social media attention and celebrity buzz. But there's an important distinction most people miss:
Ozempic (Semaglutide)
Primary Use: Ozempic is FDA-approved specifically for managing blood sugar in adults with Type 2 diabetes — it is not officially approved for weight loss in either the USA or the UK.
Despite this, its active ingredient — semaglutide — is the same compound used in Wegovy. The difference lies in the dosage. Ozempic tops out at 2 mg weekly, while Wegovy goes up to 2.4 mg specifically for weight management.
How Does Ozempic Work?
Ozempic is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone naturally released from your gut after a meal. It performs three important jobs: it stimulates insulin secretion, suppresses glucagon (which raises blood sugar), and slows gastric emptying — meaning food stays in your stomach longer, keeping you fuller.
Ozempic mimics this hormone, giving your body a prolonged GLP-1 signal throughout the week after a single injection.
Side Effects of Ozempic
The most common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly when first starting the medication or after a dose increase. These typically improve as the body adjusts. More serious but rare risks include pancreatitis, gallbladder disease, and potential kidney issues due to dehydration. The drug also carries a black-box warning regarding a rare risk of thyroid tumors in patients with a family history of medullary thyroid carcinoma.
3 What is Wegovy?
Wegovy is the weight-loss-approved version of semaglutide. Think of it as Ozempic's sibling — same molecule, but purpose-built and dosed for chronic weight management.
Wegovy (Semaglutide 2.4 mg)
Primary Use: FDA-approved and UK MHRA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.
In August 2025, Wegovy also gained approval for treating metabolic dysfunction-associated steatohepatitis (MASH) — a serious liver disease — marking a significant expansion of its use beyond weight loss.
How Wegovy Differs from Ozempic
Despite sharing the same active ingredient, the distinction matters for insurance and prescription access. Because Wegovy is specifically licensed for weight loss, insurance companies in the US are more likely to cover it for obesity-related prescriptions. In the UK, Wegovy has received NICE approval (TA875) for NHS use through specialist weight management services.
Clinical trials for Wegovy (the STEP 1 trial) showed that patients lost an average of ~15% of body weight over 68 weeks — a landmark result that hadn't been seen before outside of bariatric surgery.
Notably, a new 7.2 mg Wegovy oral tablet received FDA approval in December 2025, and early trial data from the STEP UP trial suggests this higher dose may achieve weight loss of around 21% — narrowing the gap with Mounjaro significantly.
4 What is Mounjaro? (The Newest Contender)
If Wegovy raised the bar, Mounjaro shattered it. Made by Eli Lilly, Mounjaro introduced a genuinely new mechanism to the GLP-1 world — one that may explain why its weight loss results are the most impressive we've ever seen from a medication.
Mounjaro (Tirzepatide)
Primary Use: Approved for Type 2 diabetes under the brand Mounjaro in both the US and UK. The same drug is sold as Zepbound in the US specifically for weight loss. In the UK, Mounjaro holds marketing authorization for weight management but NHS access is currently limited.
The SURMOUNT-5 clinical trial, one of the most significant obesity studies in recent history, showed participants on Mounjaro's highest dose lost an average of 22.5% of their body weight — over 20% more than what was achievable a decade ago.
The Dual-Hormone Advantage
This is what sets Mounjaro apart. While Ozempic and Wegovy only mimic the GLP-1 hormone, Mounjaro is a dual agonist — it simultaneously activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.
GIP is another hormone released after eating that enhances insulin secretion and, crucially, appears to help prevent fat from being stored in fat cells. This second mechanism is widely believed to explain why Mounjaro users experience significantly greater weight reduction than those on semaglutide-based treatments.
5 Side-by-Side Comparison Table
Here's everything you need in one place. This table is designed so you can quickly identify the key differences and similarities:
| Feature | 🔵 Ozempic | 🟢 Wegovy | 🟠 Mounjaro |
|---|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP dual agonist |
| FDA Approval (Weight Loss) | ✗ No (Diabetes only) | ✓ Yes | ✓ Yes (as Zepbound) |
| UK MHRA / NICE (Weight Loss) | ✗ No (Diabetes only) | ✓ Yes (TA875) | ✓ Yes (TA1026) |
| Injection Frequency | Once weekly | Once weekly | Once weekly |
| Average Weight Loss | 5–10% | ~15% | Up to 22.5% |
| Starting Dose | 0.25 mg/week | 0.25 mg/week | 2.5 mg/week |
| Maximum Dose | 2 mg/week | 2.4 mg/week | 15 mg/week |
| Common Side Effects | Nausea, vomiting, diarrhea, constipation — all three are similar | ||
| Cardiovascular Benefit | ✓ Proven | ✓ Proven | Trials ongoing |
| NHS Availability (UK) | Limited (diabetes) | Limited (obesity) | Very Limited (phased) |
| Best For | Diabetics needing weight support | Primary obesity treatment | Maximum weight loss |
6 Who Should Use Which?
This is the question most people really want answered. The honest answer is: it depends on your individual health profile, goals, and what your doctor recommends. But here's a practical framework:
🔵 Consider Ozempic if:
- You have been diagnosed with Type 2 diabetes
- Blood sugar control is your primary goal
- You have a history of cardiovascular disease (proven heart-protective benefit)
- Weight loss would be a welcome secondary benefit
- Your insurance covers it for diabetes
🟢 Consider Wegovy if:
- Your primary goal is weight management, not diabetes
- You have a BMI ≥30, or ≥27 with a weight-related condition
- You want an established medication with the longest weight-loss track record
- You are in the UK and seeking NHS access (more accessible than Mounjaro)
- Cost is a factor (generally cheaper than Mounjaro)
🟠 Consider Mounjaro if:
- You want the maximum possible weight loss results
- Previous GLP-1 medications haven't given you enough results
- You have both obesity and Type 2 diabetes
- You're prepared for a higher cost
- Your doctor has confirmed it's suitable for your health profile
7 Real Costs in USA vs UK
Let's talk money — because for most people, cost is a deciding factor. These medications are not cheap, and insurance coverage varies widely.
🇺🇸 United States (USD)
🇬🇧 United Kingdom (GBP)
UK: NHS vs Private — What You Need to Know
In the UK, Wegovy received NICE approval (TA875) for weight management but access through NHS specialist services remains limited due to supply constraints, with many areas operating waiting lists of 12–24 months. Mounjaro received its NICE recommendation for obesity (TA1026) in early 2025 but NHS rollout is being phased in over 12 years — currently limited to those with a BMI of 40+ and multiple weight-related conditions.
For most UK patients, private prescription remains the most realistic route for accessing either Mounjaro or Wegovy in a reasonable timeframe. Annual costs privately typically range from £2,300 to £4,200 depending on medication, dose, and whether professional support is included.
USA: Insurance Coverage Matters
In the US, insurance coverage hinges heavily on the diagnosis. Ozempic is more likely to be covered when prescribed for diabetes. Wegovy may be covered for qualifying obesity patients, though many insurance plans — including most Medicare plans — still exclude weight-loss medications. Always check your specific plan and ask your doctor about manufacturer savings programs, which can significantly reduce out-of-pocket costs.
8 Doctor's Advice — What to Ask Your Physician
Before booking an appointment, it helps to walk in prepared. Here are the questions that will genuinely make your consultation more productive:
- Am I a candidate for GLP-1 medications? — Ask your doctor to review your BMI, blood sugar levels, and any existing conditions to determine eligibility.
- Which specific drug suits my health profile? — Mention any history of thyroid issues, pancreatitis, or kidney problems, as these may influence which medication is appropriate.
- What does the dosing schedule look like? — All three start at low doses and titrate up over weeks. Understand the timeline and what to expect at each stage.
- What will this cost me with my insurance? — Ask specifically about prior authorization requirements and manufacturer assistance programs (e.g., Lilly's savings card for Mounjaro).
- How will this interact with my current medications? — GLP-1 drugs slow gastric emptying, which can affect how your body absorbs other oral medications, including contraceptive pills.
- How will we track progress? — Ask about follow-up appointments, what targets to aim for at 3 and 6 months, and the criteria for continuing treatment.
- Do I need dietary or lifestyle support? — These medications work best alongside a structured diet and exercise plan. Ask for a referral to a dietitian if needed.